1-9 of 9
Roger A. Fleischman
Close
Sort by
Journal Articles

Enhancing Anti-Tumor Immunity and Responses to Immune Checkpoint Blockade By Suppressing Interleukin-10 in Chronic Lymphocytic Leukemia

Jacqueline R. Rivas, PhDBS, Sara S. Alhakeem, PhD, Joseph M. Eckenrode, PhD, Yinan Zhang, PhD, James P. Collard, BS, Gerhard C. Hildebrandt, MD, Roger A. Fleischman, MD PhD, Li Chen, PhD, Jon S. Thorson, PhD, Markos Leggas, PhD, Subbarao Bondada, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5486.
https://doi.org/10.1182/blood-2019-127178
Published: 2019
Journal Articles

Socioeconomic Disparities Affect Survival of Classical Hodgkin Lymphoma in a Statewide Cancer Registry Analysis

Zin W. Myint, MD, Runa Shrestha, MBBS, Quan Chen, Bin Huang, Amit Goldberg, MD, Reshma Ramlal, MD, Gregory Monohan, MD, Roger A. Fleischman, MD PhD, Roger H. Herzig, MD, Gerhard Carl Hildebrandt, MD, Hayder Saeed, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4836.
https://doi.org/10.1182/blood-2018-99-110988
Published: 2018
Journal Articles

Novel role of prostate apoptosis response-4 tumor suppressor in B-cell chronic lymphocytic leukemia

Mary K. McKenna, Sunil K. Noothi, Sara S. Alhakeem, Karine Z. Oben, Joseph T. Greene, Rajeswaran Mani, Kathryn L. Perry, James P. Collard, Jacqueline R. Rivas, Gerhard C. Hildebrandt, Roger A. Fleischman, Eric B. Durbin, John C. Byrd, Chi Wang, Natarajan Muthusamy, Vivek M. Rangnekar, Subbarao Bondada
Journal: Blood
Blood (2018) 131 (26): 2943–2954.
https://doi.org/10.1182/blood-2017-10-813931
Published: 2018
Includes: Supplemental data
Journal Articles

Consolidative Radiation with Chemotherapy in Early Stage Classical Hodgkin Lymphoma with Unfavorable Risk: The Kentucky Experience

Zin W Myint, MD, Runa Shrestha, MD, Jaclyn Nee, Bin Huang, Eric Durbin, Stacey Slone, Amit Goldberg, Maryam Zia, Reshma Ramlal, MD, Gregory Monohan, MD, Roger H. Herzig, MD, Roger A. Fleischman, MDPhD, Gerhard Carl Hildebrandt, MD, Hayder Saeed, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5184.
https://doi.org/10.1182/blood.V130.Suppl_1.5184.5184
Published: 2017
Journal Articles

Sustained Remissions after Discontinuation of Ibrutinib in Relapsed/Refractory CLL: A Basis for Reducing Drug Toxicity and Treatment Costs?

Jenna Houranieh, PharmD, Roger A Fleischman, MD, PhD
Journal: Blood
Blood (2016) 128 (22): 5600.
https://doi.org/10.1182/blood.V128.22.5600.5600
Published: 2016
Journal Articles

Changes in Killer-Cell Immunoglobulin-like Receptor (KIR) Expression on NK Cells Following DNA Demethylation By Azacitidine in Relapsed and Refractory Lymphomas

Runa Shrestha, MD, Ahmad Al-Attar, MD, John W Hayslip, MD, Lutz T Charles, MD, Emily Dressler, PhD, Jabbour Hossam, MD, Maryam F Zia, MD, Hayder Saeed, MD, Amit Goldberg, MD, Gregory Monohan, MD, Roger Herzig, MD, Roger A Fleischman, MD, PhD, Gerhard Hildebrandt, MD, Shams A Shakil, MD, PhD
Journal: Blood
Blood (2016) 128 (22): 5296.
https://doi.org/10.1182/blood.V128.22.5296.5296
Published: 2016
Journal Articles

Ibutinib-Associated Autoimmune Hemolytic Anemia in CLL

Jacob Hodskins, MD, Jenna Houranieh, PharmD, Roger A. Fleischman, MD PhD
Journal: Blood
Blood (2014) 124 (21): 5671.
https://doi.org/10.1182/blood.V124.21.5671.5671
Published: 2014
Journal Articles

A HoxD11 Homeobox Gene Mutation Associated With Congenital Absent Radius But Without The Thrombocytopenia Of The TAR Syndrome Or a HoxA11 Mutation

Roger A. Fleischman, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 4837.
https://doi.org/10.1182/blood.V122.21.4837.4837
Published: 2013
Journal Articles

Analysis of the hematopoietic potential of muscle-derived cells in mice

Brief Report
Hartmut Geiger, Jarrod M. True, Barry Grimes, Elizabeth J. Carroll, Roger A. Fleischman, Gary Van Zant
Journal: Blood
Blood (2002) 100 (2): 721–723.
https://doi.org/10.1182/blood.V100.2.721
Published: 2002